Method of thrombin time normalisation in newborn calves with iron-deficient anemia

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

 

The invention relates to biology and veterinary medicine, namely to hamostaseologie.

The closest analogue to the proposed method of normalization trombonology time of newborn calves with iron deficiency anemia can be considered EN 2403025 "Way to normalize thrombin time with anemia of newborn calves and piglets". In the prototype, as well as in the claimed method, is applied feroglobin, but in the form of a double introduction, posted on 2 injections with an interval of 10 days, which lengthens the time of correction, not individualsare the amount of iron introduced into the body of the calf. Also used in the prototype in conjunction with the preparation of iron 2 metabolically active drugs do way "bulky" and difficult to implement in industrial farming. While the claimed method is simple and easy in its application in practice to achieve the correction of thrombin time in newborn calves with iron deficiency anemia for 6 days versus 10 days in the prototype. In addition, glicerina (N-acetylglucosaminyl-N-acetyl-muramyl-alanyl-D-isoglutamine) (Andronov T.M., Pinegin B.V., goats I.G., Ustinov GI Application immunomodulator of glicerina for the prevention and treatment of animal diseases. Methodical recommendations. Moscow, 2009. - 12 C.)used in the claimed method, previously settled and isolated its application, nor when combined with some means were not found ability to influence the duration of the thrombin time of newborn calves with iron deficiency anemia to normalize thrombin time.

The aim of the invention is the normalization of thrombin time in newborn calves with iron deficiency anemia.

The essence of the proposed method lies in the fact that for the normalization of thrombin time newborn calves with iron-deficiency anemia is assigned solution feroglobin-75 (1 ml)containing 75 mg of iron per 1 ml of solution at a ratio of 15 mg of iron per 1 kg body weight of the calf intramuscularly once in combination with the feeding of glicerina at 6.0 mg/day in the morning (dissolved in a small amount (50,0-100,0 ml) of water or milk, or colostrum, intended to feed the calf) for 6 days, starting simultaneously with the injection feroglobin.

The method allows to normalize thrombin time of newborn calves with iron deficiency anemia on the next day after completion of treatment, taking it to the level characteristic for healthy calves that will allow newborn calves with iron deficiency anemia significantly reduce the risk of thrombotic complications, to improve the health of the herd, improving trophic their tissues and, consequently, to accelerate growth in the future to increase the number of floors the target meat and dairy products, minimizing the case.

The inventive method is carried out as follows.

For the diagnosis of newborn calves with anemia violations thrombin time undergoing assessment by the following methodology Scenarion, Apomu. Osnovy diagnosis of disorders of hemostasis. Moscow, 1999, the publishing house "Novamed-JSC. - s).

The principle of the method: determine the clotting time of the plasma under the influence of thrombin, standardized by activity in normal control plasma. Thrombin test characterizes the kinetics of the final stage of blood coagulation is the rate of conversion of fibrinogen to fibrin.

Used reagents: 1. Tris-buffer, M (or Michaelis buffer), pH 7.3 to 7.4. 2. A solution of thrombin in buffer activity 14-16 sec. The working solution of the reagent prepared in a plastic or silikonizirovannoj vitro and used the day of the examination. Stored at room temperature.

The research material is citrate plasma calf.

To 0.2 ml of the investigated plasma heated in a water bath at +37°C for 1 min, add 0.2 ml of thrombin (to which research should have a temperature not higher than +18-25°C). Immediately include stopwatch and note the clotting time.

The determination is performed manual or coagulometer.

The results are expressed in seconds, comparing the clotting time in control of InEU normal (reference) and investigated the plasma. Normal thrombin time (TV) is 14-16 sec. When iron deficiency anemia in calves observed acceleration of the TV.

When accelerating TV newborn calves with iron deficiency anemia need for treatment according to the stated method: feroglobin-75 (1 ml) at a rate of 15 mg of iron per 1 kg body weight of the calf within the muscle, once and feeding of glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin.

Example 1. The newborn calf No. 26 with iron deficiency anemia, the 2nd day of life, weight 31 kg, the violation of erythropoiesis with signs of decreased levels of iron in his body, accompanied by a change of blood. Thus, the amount of hemoglobin it was 84,2 g/l, erythrocytes of 4.00×1012/l, sideration of 1.0% when the level of iron in serum of 12.4 µmol/L. When the survey was detected acceleration of thrombin time (12 sec). The calf was assigned to 6.2 ml feroglobin-75 intramuscularly once and the feeding of glicerina at 6.0 mg/day in the morning when mixing it with a 50.0 ml of colostrum within 6 days, starting simultaneously with the injection feroglobin.

The next day after the end of treatment for calf normalization red blood count hemoglobin he was 116,0 g/l, erythrocytes was 4.76×1012/l when the number is of iteration 7.7% and the level of iron in serum of 21.2 μmol/L. The animal was achieved full normalization of thrombin time (15 sec), remaining stable thereafter.

Example 2. The newborn calf No. 29 with iron deficiency anemia, the 4th day of life, weight 29 kg, the violation of erythropoiesis with signs of decreased levels of iron in his body, accompanied by a change of blood. Thus, the amount of hemoglobin it amounted to 82.1 g/l, erythrocytes to 3.92×1012/l, sideration of 1.0% when the level of iron in serum 11.3 µmol/L. When the survey was detected acceleration of thrombin time (11 seconds). The calf was assigned to 5.8 ml feroglobin-75 intramuscularly once and the feeding of glicerina at 6.0 mg/day in the morning when mixing it with a 100.0 ml of milk for 6 days, starting simultaneously with the injection feroglobin.

The next day after the end of treatment for calf normalized red blood count hemoglobin he was to 118.0 g/l, erythrocytes with 4.65×1012/l, sideration of 7.4% when the level of iron in serum of 20.8 µmol/l, was achieved full normalization of thrombin time (16 seconds), remaining stable thereafter.

The use of the proposed method to normalize thrombin time in biology and veterinary medicine will help to avoid thrombotic complications in newborn calves with iron deficiency is a nemia, to improve the health of the herd, to reduce mortality and increase the volume and quality in the future of meat and dairy products and get these animals healthy offspring.

The claimed method is tested on 145 newborn calves with iron deficiency anemia, which showed 100% efficiency correction of iron deficiency anemia and thrombin time.

The method of normalization of thrombin time in newborn calves with iron deficiency anemia, characterized by use in combination with ferroaluminum-75 at the rate of 15 mg of iron per 1 kg of body weight of the calf intramuscularly, once the drug glycodin, giving to drink at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes the pyrrolo- and thiazolopyridinium compounds and their pharmaceutically acceptable salts covered by general structural formula I: wherein the values A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are those as presented in cl.1, and a pharmaceutical composition based on the given compound for inhibition of hypoxia-inducible factor (HIF) hydroxylase activity.

EFFECT: there are produced and described new compounds able to modulate hypoxia-inducible factor (HIF) stability and/or activity.

29 cl, 178 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel cyanoisoquinoline derivatives of formula I , where R is selected from a group comprising hydrogen and C1-C10 alkyl, R1, R2, R3 and R4 are independently selected from a group comprising hydrogen, halogen, hydroxy, C1-C10 alkyl, substituted with 1-3 halogen atoms or C6-C14 acryl, C6-C14 aryl, -OR7, -SR7 and -SO2R7, where R7 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14 aryl, C3-C10 cycloalkyl, C6-C14 aryl and C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are optionally substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino and C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, and R5 and R6 are independently selected from a group comprising hydrogen and C1-C3 alkyl, or pharmaceutically acceptable salts thereof. The invention also relates to novel cyanoquinoline derivatives of formula II , where R31, R32, R33 and R34 are independently selected from a group comprising hydrogen, hydroxy, halogen, C1-C10 alkyl substituted with 1-3 halogen atoms or with C6-C14 aryl, C6-C14 aryl, -OR37, -SR37 and -SO2R37, where R37 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14aryl, C3-C10 aryl, C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, R35 denotes hydrogen or methyl, or pharmaceutically acceptable salts thereof. The invention also relates to specific cyanoisoquinoline compounds, a pharmaceutical composition based on the compound of formula I, a hypoxia-inducible factor (HIF) hydroxylase inhibiting method, a method of treating, preventing or slowing down development of a condition associated with hypoxia-inducible factor (HIF), a condition associated with erythropoietin (EPO), anaemia, based on use of the compound of formula I.

EFFECT: obtaining novel cyanoisoquinoline compounds having useful biological properties.

42 cl, 1 tbl, 54 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to an oral food additive which contains anhydrous ferric pyrophosphate, ferric pyrophosphate monohydrate or nonahydrate and copper citrate. The invention also concerns a method for preparing said additive and using it for balanced iron intake in the patient.

EFFECT: additive under the invention has no unpleasant metal taste even in the absence of flavouring and taste masking ingredients.

19 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science. The preparation contains a mixture of colloidal iron, a ligand, zinc, cobalt, selenium and water. The ligand is presented by Triton X-100 (polyethylene glycol mono (tetramethylbutanol) phenyl ester) in the following proportions, mg: colloidal iron (III) 35.0-45.0; Triton X-100 0.2÷0.6; zinc (II) 0.1÷0.3; cobalt (II) 0.05÷0.15; selenium (IV) 0.02÷0.04 and water up to 1000.0.

EFFECT: preparation exhibits high therapeutic and preventive efficacy, low toxicity, keeps dispersion and shows high storage stability.

5 cl, 12 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: invention relates to pharmaceuticals and medicine and pharmaceutically acceptable derivatives of 2-aminobenzothiazole of general formula 1.

EFFECT: high anti-hypoxic activity and high effectiveness of treatment.

7 cl, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely obstetrics, and can be used for treating anaemia in pregnant women. For this purpose, iron preparations are added with Poetam 900 mg/day. The length of the therapeutic course is 3 weeks in moderate severity of anaemia, 6 weeks - in severe anaemia, and 8 weeks - in very severe anaemia.

EFFECT: method provides intensified therapeutic effect ensured by stimulating production of endogenous renal erythropoietin and higher concentration of sulphhydryl groups and lipoproteins in red blood cell membranes with no side effects.

6 tbl, 1 ex

FIELD: medicaments.

SUBSTANCE: present invention provides water-soluble iron-carbohydrate derivative complexes which are suitable for the therapy of iron deficiency states, and the preparation thereof, medicaments comprising them, and the use thereof in the prophylaxis or therapy of iron deficiency states. The medicaments are suitable in particular for parenteral administration. A water-soluble iron-carbohydrate derivative complex obtained from the reaction of an aqueous iron (III) salt solution and (b) an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins, wherein the oxidation is carried out with an aqueous hypochlorite solution at a pH value in the alkaline range, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40, and the subsequent derivatization is carried out with a suitable reagent. The process for the preparation of the iron-carbohydrate complex, wherein one or more maltodextrins is oxidized in aqueous solution, at an alkaline pH value, with an aqueous hypochlorite solution, the subsequent derivatization is carried out with a suitable reagent, and the resulting solution is reacted with the aqueous solution of an iron (III) salt, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40.

EFFECT: most derivatised maltodextrin ligands exhibit increased stability towards enzymatic degradation by amylase as compared with underivatised maltodextrin, which can promote retarded and uniform degradation of the iron-maltodextrin derivative complexes according to the invention in the body.

15 cl, 11 tbl, 45 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is haemostimulating medicine, representing immobilised on polymer recombinant erythropoietin, characterised by the fact that recombinant erythropoietin is immobilised by electron-emitting impact by its introduction into solution of low-molecular water-soluble polymer (PEG, polyvinyl pyrrolidone, hydroxyethyl starch with molecular weight 400-4000 Da), preliminarily subjected to impact of ionising irradiation in dose 1-5 Mrad, to final concentration 500-5000 IU in 1 ml of solution. Shown is more expressed specific activity of medication in case of parenteral and per oral intake in comparison to medication "Mircera".

EFFECT: claimed medication does not possess immunogenic properties and does not demonstrate signs of allergenic action.

4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology, and can be applied for treatment of hereditary anemias, associated with failure of porphyrine synthesis. For this purpose per orally introduced is 5-aminolevulinic acid or its hexyl ether in doses, which insure compensation of insufficient biosynthesis of 5-aminolevulinic acid by organism.

EFFECT: method insures fast and effective increase of hemoglobin level in treatment of said pathology in experiment.

3 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medications and deals with composition for enhancing growth of hematopoetic stem cells CD34+, which contains efficient amount of immunomodelling compound, which represents 4-(amino)-2-(2,6-dioxo(3-pyperidyl))isoindoline-1,3-dione or 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)pyperidine-2,6-dione or its pharmaceutically acceptable salt and efficient amount of valproic acid or trichostatin A or their pharmaceutically acceptable salt. Invention also relates to method of enhancing growth of hematopoetic stem cells CD34+, method of treatment, prevention or controlling hematological disease or disorder, method of transplantation and recovery of bone marrow, method of treatment, prevention or controlling solid tumour, method of treatment, prevention or controlling leukoses and myelomas, method of treatment, prevention or controlling myelodysplastic syndrome and method of increasing expression of embryonic hemoglobin in cells.

EFFECT: compositions by the invention synergistically increase growth of hematopoetic stem cells CD34+.

23 cl, 16 dwg

FIELD: medicaments.

SUBSTANCE: present invention provides water-soluble iron-carbohydrate derivative complexes which are suitable for the therapy of iron deficiency states, and the preparation thereof, medicaments comprising them, and the use thereof in the prophylaxis or therapy of iron deficiency states. The medicaments are suitable in particular for parenteral administration. A water-soluble iron-carbohydrate derivative complex obtained from the reaction of an aqueous iron (III) salt solution and (b) an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins, wherein the oxidation is carried out with an aqueous hypochlorite solution at a pH value in the alkaline range, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40, and the subsequent derivatization is carried out with a suitable reagent. The process for the preparation of the iron-carbohydrate complex, wherein one or more maltodextrins is oxidized in aqueous solution, at an alkaline pH value, with an aqueous hypochlorite solution, the subsequent derivatization is carried out with a suitable reagent, and the resulting solution is reacted with the aqueous solution of an iron (III) salt, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40.

EFFECT: most derivatised maltodextrin ligands exhibit increased stability towards enzymatic degradation by amylase as compared with underivatised maltodextrin, which can promote retarded and uniform degradation of the iron-maltodextrin derivative complexes according to the invention in the body.

15 cl, 11 tbl, 45 ex

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear cation nitrosyl iron complexes with natural aliphatic thiolyls with general formula [Fe2(SR)2(NO)4]SO4 where R is aliphatic ligands of natural origin.

Also there is proposed method for production of binuclear cation nitrosyl iron complex, nitrogen monoxide donor, inductor of tumor cells apoptosis, application binuclear cation nitrosyl iron complex, pharmaceutical composition and set used for treatment of oncology diseased. The technical result is EFFECT: production of binuclear cation nitrosyl iron complex possessing cytotoxic, apoptotic and NO-donor activity.

15 cl, 2 ex, 4 tbl, 7 dwg

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear nitrosyl iron complexes with benzazeheterocyclic derivatives with general formula [Fe2(SR)2(NO)4] where R is And where X is NH, S, R1 is lower alkyl. Also there is proposed method for its production, nitrogen monoxide donor, application as oncology drug and for production of oncology drug, pharmaceutical composition and set used for treatment of oncology diseased.

EFFECT: production of binuclear nitrosyl iron complex that is used as an oncology drug with increased effectiveness and decreased toxicity.

15 cl, 3 ex, 4 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to medication, applied in case of myocardial infarction and operations on heart in conditions of artificial blood circulation. Water-soluble composition for intravenous introduction, contains ingredients with the following component ratio in wt %: D-glucose 23.40-28.60; potassium chloride 0.14-0.16; potassium salt of L-asparaginic acid 0.81-0.99; semi-magnesium salt of L-asparagenic acid (magnesium L-aspartate) 0.72-0.88; human insulin genetically engineered (in IU/l) 54.00-66.00; dinitrosyl complex of iron (II) with glutathione 0.19-0.23; water for injections - remaining part, with solution pH 7.4±0.1 at 22°C.

EFFECT: application of composition ensures limitation of myocardial infraction size, recovery of metabolic condition of heart at reperfusion, reduces injury of membranes of post-ischemic cardiomyocytes with smaller haemodinamics disorders as compared with traditionally applied medications.

2 dwg, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of a tetranitrosyl complex of iron with thiophenol of formula [Fe2(SC6H5)2(NO)4] as an anti-tumour medicinal agent in order to prepare a medicinal agent for treating oncological diseases. The invention also relates to a pharmaceutical composition and a set containing said complex.

EFFECT: invention ensures high efficiency of treatment.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to complex compound of iron with carbohydrate. Complex compound, in addition to iron (III) contains iron (II). Per cent of iron (II) in terms of total amount of iron in complex compound constitutes, at least, 2 wt %. Carbohydrate is selected from group, consisting of natural carbohydrates or synthetic derivatives of carbohydrates, such as starch, hydrolysed starches, dextrins, in particular such as maltodextrin, maltose syrup, glucose syrup, cyclodextins, dextrans, saccharides. Per cent of carbohydrate in terms of complex compound of iron with carbohydrate constitutes from 10 to 80 wt %. Method of obtaining complex compound of iron with carbohydrate includes the following stages. Water solution of suspension of carbohydrate is prepared. After that, iron (III) salts are added at constant pH value within the range from 7 to 13. Iron (III) salt is selected from group, consisting of iron (III) chloride and iron (III) sulfate. Water solution or suspension is heated with further cooling. Formed complex compound of iron with carbohydrate if isolated. Precipitation of complex compound of iron with carbohydrate is performed by addition of one or more alcohols, such as ethanol or propanol. Obtained complex compound is used for production of medication for treatment of iron-deficient anemias, which is well absorbed in organism in case of peroral intake.

EFFECT: iron, included into composition of medication is better resorbed and better tolerated by organism than pure iron preparations.

26 cl, 1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, in particular deals with composition with prolonged release of active substance, representing iron source, containing at least one coated granule, said coated granule consisting of particle, which contains said active substance, covered with at least two coats, containing combination of excipients, as well as to method of obtaining it. Claimed compositions can be used for obtaining medication, intended for treatment and/or prevention of iron deficiency and anemia, induced by iron deficiency.

EFFECT: invention provides composition with prolonged release of active substance, possessing high stability and ensuring protection of active substance from oxidation.

30 cl, 2 ex, 3 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves three intramuscular introduction of ferroglucin 75 mg (1 ml) every 5 days, three intramuscular introduction of phosprenyl by different syringes in different points simultaneously with an iron preparation, 0.12 ml/kg for the first injection, 0.10 ml/kg for the second injection, 0.08 ml/kg for the third injection, and the intramuscular injections of gamavit 0.018 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to prevent vascular complications in newborn calves with anaemia, to optimise microcirculation and tissue trophism, to hasten the growth, to improve a herd, to produce greater amount of meat production, to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves prescription of two intramuscular injection of ferroglucin 150 mg (2 ml) every 10 day, three intramuscular injections of phosprenyl in different syringes into different points, 0.12 ml/kg for the first time together with an iron agent, 0.10 ml/kg five days after the first injection of ferroglucin, 0.07 ml/kg for the third time together with the second injection of ferroglucin and intramuscular injections of gamavit 0.020 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to normalise spontaneous erythrocyte aggregation in suckling calves with anaemia, to provide higher additional weights, to reduce mortality and to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. Method involves the prescription to calves and piglets of two intramuscular injections of ferroglucin 150 mg (2 ml) every 5 days, two intramuscular injections of phosprenyl in different syringes into different points in dosage 0.09 ml/kg together with the injections of ferroglucin, and the intramuscular injections of gamavit 0.02 ml/kg once a day for five days running together with the first injection of ferroglucin.

EFFECT: method allows to normalise thrombin time in newborn calves and piglets with anaemia in 4 days after the termination of treatment to be brought close to such in healthy calves and piglets.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to pharmaceutical industry and deals with disulfiram preparations. Medical form of disulfiram with prolonged action contains, at least, one microsphere from disulfiram, covered with first stabilising nanosize coating from neutral polysaccharides or gelatin, enclosed in second, spatially linked coating in form of microcapsule from neutral polysaccharides. Invention also deals with method of obtaining medical form of disulfiram with prolonged action.

EFFECT: application of claimed inventions ensures durative effect of prolonged action of disulfiram, stabile kinetics of drug release into tissues, sparing procedure of drug introduction and excludes possibility of its independent removal.

7 cl, 9 ex, 3 dwg

Up!